BARD1 and breast cancer: Among BRCA2 mutation carriers, 84.5% had a preference for being ER-positive with a molecular subtype of luminal A (71%), while only 54.5% of BARD1 mutation carriers developed ER-positive breast cancer (p-value = 0.022), with 30% in the molecular subtype of luminal A. In our BARD1 mutation carriers, we observed that 50% of them harbored TNBC, a frequency similar to that of BRCA1 mutation carriers (58.2%).